Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ImmuneOncia Therapeutics, Inc","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics, ImmuneOncia Enter Into Manufacturing Development Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ImmuneOncia Therapeutics, Inc","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","amount":"$470.0 million","upfrontCash":"$8.0 million","newsHeadline":"ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ImmuneOncia Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by ImmuneOncia Therapeutics, Inc

    Menu

    ImmuneOncia Therapeutics, Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ImmuneOncia Therapeutics, Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia

              Details:

              IMC-001 is a PD-L1 antibody, an immune checkpoint inhibitor. This antibody activates the anticancer functions of T cells by strongly inhibiting the binding between PD-1 expressed on T cells and PD-L1 expressed on the surface of cancer cells.

              Lead Product(s): IMC-001

              Therapeutic Area: Oncology Product Name: IMC-001

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmuneOncia Therapeutics, Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China

              Details:

              The agreement includes uses of IMC-002 for oncology indication as a monotherapy or combination agent in the Territory of Greater China (Mainland China, Hong Kong, Macau, and Taiwan).

              Lead Product(s): IgG4 monoclonal antibody

              Therapeutic Area: Oncology Product Name: IMC-002

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: 3D Medicines Corporation

              Deal Size: $470.0 million Upfront Cash: $8.0 million

              Deal Type: Collaboration March 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmuneOncia Therapeutics, Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Samsung Biologics, ImmuneOncia Enter Into Manufacturing Development Agreement

              Details:

              Samsung Biologics will provide a full scope of CDO services from cell line development, process development, non-clinical and clinical material manufacturing, to IND submission support for global clinical trials of five candidates from ImmuneOncia's pipeline.

              Lead Product(s): IMC-002

              Therapeutic Area: Oncology Product Name: IMC-002

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Samsung Biologics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY